Karyopharm Therapeutics (KPTI) SEC Filings: History & Chart

Karyopharm Therapeutics Inc.(KPTI)

Biotechnology · Newton, MA

$0.68+0.01 (+1.36%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Newton, MA

228 employees

www.karyopharm.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard A. Paulson

View full financials

Form	Filing Date	Accepted	Document
4	Oct 2, 2026	Oct 2, 2026	View filing
SC 13G/A	Sep 25, 2026	Sep 25, 2026	View filing
SC 13G/A	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 18, 2026	Sep 18, 2026	View filing
8-K	Sep 11, 2026	Sep 11, 2026	View filing
SC 13G	Sep 4, 2026	Sep 4, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
8-K	Aug 31, 2026	Aug 31, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G/A	Aug 12, 2026	Aug 12, 2026	View filing
SC 13G/A	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
SC 13G	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 17, 2026	Jul 17, 2026	View filing
SC 13G/A	Jun 5, 2026	Jun 5, 2026	View filing
8-K	May 28, 2026	May 28, 2026	View filing
S-8	May 27, 2026	May 27, 2026	View filing
S-8	May 27, 2026	May 27, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
4	May 26, 2026	May 26, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing

SEC Filings

Recent Filings